We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+2.89%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.86B
AUM Growth
+$29.2M
Cap. Flow
+$147M
Cap. Flow %
5.13%
Top 10 Hldgs %
48.59%
Holding
107
New
12
Increased
2
Reduced
2
Closed
19

Top Buys

Rank Stock Value
1
TYRA icon
Tyra Biosciences
TYRA
+$121M
2
TNGX icon
Tango Therapeutics
TNGX
+$82.4M
3
BPMC
Blueprint Medicines
BPMC
+$39.6M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$37.4M
5
NUVL
Nuvalent
NUVL
+$35.1M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$63.2M
2
AMRN
Amarin Corp
AMRN
+$26.3M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$24M
4
AGEN
Agenus
AGEN
+$22M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$20.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.15%
2 Financials 0.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
76
MoonLake Immunotherapeutics
MLTX
$1.57B
$3.98M 0.14%
400,000
– –
OBIO icon
77
Orchestra BioMed
OBIO
$238M
$3.96M 0.14%
400,000
– –
LJPC
78
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.55M 0.12%
890,700
– –
KNSA icon
79
Kiniksa Pharmaceuticals
KNSA
$5.8B
$3.31M 0.12%
290,577
– –
LABD icon
80
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$71M
$3.19M 0.11%
+15,000
New +$3.19M
GNCA
81
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.18M 0.08%
1,134,453
– –
SNCE
82
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$1.96M 0.07%
10,000
– –
OMEG
83
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$1.95M 0.07%
200,000
– –
TARA icon
84
Protara Therapeutics
TARA
$220M
$1.45M 0.05%
209,227
– –
SRZN icon
85
Surrozen
SRZN
$258M
$1.42M 0.05%
+13,333
New +$1.88M
CLRB icon
86
Cellectar Biosciences
CLRB
$20.5M
$851K 0.03%
3,067
– –
NUVB.WS
87
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$683K 0.02%
266,666
– –
MRNA icon
88
PUT
Moderna
MRNA
$21.8B
$253K 0.01%
+10,000
New +$3.69M
AGEN
89
Agenus
AGEN
$312M
– –
-203,800
Closed -$22M
AMRN
90
Amarin Corp
AMRN
$299M
– –
-300,000
Closed -$26.3M
ATXS
91
DELISTED
Astria Therapeutics
ATXS
– –
-295,833
Closed -$3.75M
BMRN icon
92
BioMarin Pharmaceuticals
BMRN
$11.6B
– –
-250,000
Closed -$20.9M
BOLT icon
93
Bolt Biotherapeutics
BOLT
$7.67M
– –
-2,500
Closed -$773K
ESPR
94
DELISTED
Esperion Therapeutics
ESPR
– –
-500,000
Closed -$10.6M
IMVT icon
95
Immunovant
IMVT
$7.93B
– –
-1,000,000
Closed -$10.6M
MIRM icon
96
Mirum Pharmaceuticals
MIRM
$6.46B
– –
-317,000
Closed -$5.48M
MREO
97
Mereo BioPharma
MREO
$54.7M
– –
-6,226,673
Closed -$19.7M
MTNB icon
98
Matinas BioPharma
MTNB
$1.88M
– –
-229,573
Closed -$8.89M
QURE icon
99
uniQure
QURE
$3.03B
– –
-250,000
Closed -$7.7M
SYRE icon
100
Spyre Therapeutics
SYRE
$8.54B
– –
-22,000
Closed -$3.83M
1 2 3
4
5

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Boxer Capital held 107 positions worth $2.86B, up 1% from $2.83B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Boxer Capital deployed $147M of net new capital in Q3 2021, opening 12 new positions and adding to 2 existing holdings. Its largest new stake was Tyra Biosciences: 6,323,359 shares worth $111M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Solid Biosciences, an estimated $1.42M trimmed.

  • Boxer Capital's largest Q3 2021 buy was Tyra Biosciences: 6,323,359 shares worth $111M.
  • Boxer Capital added most to Kinnate Biopharma Inc. Common Stock in Q3 2021, an estimated $17M increase.
  • Boxer Capital's biggest Q3 2021 reduction was Solid Biosciences, cutting an estimated $1.42M.
  • Boxer Capital fully exited Seagen Inc. Common Stock in Q3 2021, selling an estimated $63.2M.
  • Boxer Capital's ten largest holdings make up 49% of its $2.86B portfolio in Q3 2021.
  • Boxer Capital opened 12 new positions and closed 19 in Q3 2021.
  • Boxer Capital's portfolio value rose 1% quarter-over-quarter to $2.86B.

Based on Boxer Capital's 13F filing for Q3 2021, filed 15 Nov 2021.